Targeting beta-lactamase activity with Oxacyclohexadecan-2-one in carbapenem-resistant uropathogenic E. coli: A

Priyanka Balaji1, Madhana Priya N2,3, Emmanuel Bhaskar M4

  • 1Department of Human Genetics, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

Plos One
|February 18, 2025
PubMed

Insights

Moringa oleifera seed compound Oxacyclohexadecan-2-one shows potent antibacterial activity against carbapenemase-producing E. coli. This natural compound exhibits higher binding affinity than Imipenem, suggesting a promising new treatment for urinary tract infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Computational Chemistry

Background:

  • Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (E. coli) are a global health problem.
  • Rising antibiotic resistance necessitates the development of novel therapeutic strategies.
  • Carbapenemase-producing E. coli strains, such as those expressing blaNDM-1, blaNDM-5, and blaOXA-48, pose a significant clinical challenge.

Purpose of the Study:

  • To investigate the antibacterial potential of Oxacyclohexadecan-2-one, a compound derived from Moringa oleifera seed.
  • To evaluate its efficacy against key carbapenemase-producing E. coli proteins (blaNDM-1, blaNDM-5, blaOXA-48).
  • To compare its binding affinity and stability with the antibiotic Imipenem using molecular docking and dynamic simulations.

Main Methods:

  • Ethanolic extract of Moringa oleifera seed was analyzed using Gas Chromatography-Mass Spectrometry (GC-MS).
  • PyRx virtual screening was employed to identify potential drug candidates based on the Rule of 5 and ProTox criteria.
  • Molecular docking and 100 ns molecular dynamic simulations were performed for Oxacyclohexadecan-2-one and Imipenem against target proteins.

Main Results:

  • Oxacyclohexadecan-2-one demonstrated superior binding affinity to blaNDM-1, blaNDM-5, and blaOXA-48 proteins compared to Imipenem.
  • Docking scores for Oxacyclohexadecan-2-one were -6.45, -6.05, and -7.34 kcal/mol, respectively, outperforming Imipenem's scores (-3.41, -3.99, -6.36 kcal/mol).
  • Molecular dynamics simulations indicated favorable stability and binding interactions for Oxacyclohexadecan-2-one-protein complexes.

Conclusions:

  • Oxacyclohexadecan-2-one exhibits significant potential as an antibacterial agent against carbapenemase-producing E. coli.
  • Its strong binding affinity and stable interactions suggest it could be a promising lead compound for developing new UTI treatments.
  • Further research is warranted to explore its therapeutic applications and optimize its efficacy.